Teva Pharmaceutical Industries Ltd. (NYSE: TEVA; TASE: TEVA) CEO Erez Vigodman said today, "If the Mylan Pharmaceuticals shareholders support the acquisition of Perrigo, Teva will abandon its bid forMylan." Vigodman made his remarks at a meeting held for its institutional shareholders. Teva has been attempting a hostile takeover of Mylan (MYL) in recent months by communicating with the US company's shareholders directly. Its measures have led to confrontations between the Mylan chairman and the TevaCEO, who exchanged written barbs. Teva offered $41 billion for Mylan, at $82 a share. Mylan hasrepeatedly asserted that the deal is not good for its shareholders, due to the difference between the companies. RELATED ARTICLES Teva CEO: The industry is undergoing a shakeup "Teva's Mylan stake a psychological factor" Benny Landa: Teva would be wrong to buy Mylan For its part, Mylan has offered to acquire Perrigo Company (NYSE:PRGO; TASE:PRGO) for $34.1 billion, an offer Perrigo has refused. Published by Globes [online], Israel business news - www.globes-online.com - on July 5, 2015 © Copyright of Globes Publisher Itonut (1983) Ltd. 2015
